NCT05137600 - A Drug-Drug Interaction Study Between ATI-2173 and Midazolam or Clarithromycin in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 28, 2021

Primary Completion Date

December 23, 2021

Study Completion Date

January 23, 2022

Conditions

Drug Drug Interaction

Interventions

DRUG

ATI-2173

ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth

DRUG

Midazolam

Midazolam is a sensitive CYP3A index substrate

DRUG

Clarithromycin

Clarithromycin is a sensitive P-gp index inhibitor to evaluate potential effect of P-gp inhibition on ATI-2173 and its metabolites(clarithromycin)

Trial Locations (1)

H3P 3P1

Altasciences, Montreal